Linn Hodneland

Statistics

Publications

Citations

H-Index

Active since

2018

Affiliations

University of Bergen(Current)

BerGenBio (Norway)

Linn Hodneland is an author at University of Bergen specializing in immune checkpoint inhibitor therapy, immunology, and receptor tyrosine kinase activation.

Publications per year

2018–2024

Publications

Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.

Murray Yule, Kjersti Davidsen, Magnus Bloe et al. · Journal of Clinical Oncology · 2018 · 20 citations

Life Sciences, Immunology, Pharmacology +17

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

Sturla Magnus Grøndal, Anna Tutusaus, Loreto Boix et al. · Frontiers in Immunology · 2024 · 14 citations · Full text

Life Sciences, Cell Biology, Immunology +17

1–2 of 2